Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Collaborators: Hoffmann-La Roche; Roche Pharma AG
• Treatments: Interferon-alpha; Peginterferon alfa-2a

Criteria

Inclusion Criteria:

• Completion of HALT-C Trial, in either treatment or non-treatment arm

Exclusion Criteria:

• Non-completion of HALT-C Trial

• Patients who do not wish to be treated with peginterferon after the first portal pressure measurement

• Hepatocellular Carcinoma

• Underlying autoimmune disorder

• Currently being treated with immune suppressive agent

• Illicit drug use

• Alcohol use of more than 6 grams per day

• Advanced cardiopulmonary disease

• Uncontrolled diabetes mellitus

• Patients who, in the opinion of the investigator, should not participate in this trial